Coherus BioSciences (CHRS) Tops Q2 EPS by 7c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.42 +3.65%
Revenue Growth %: +37.8%
Financial Fact:
Interest expense: -3.14M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +37.8%
Financial Fact:
Interest expense: -3.14M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $14.31 million versus the consensus estimate of $14.41 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- BofA Securities Downgrades Smith & Nephew PLC. (SN:LN) (SNN) to Neutral
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
